Dasiglucagon is used in the treatment of Hypoglycemia in Type 1 and Type 2 Diabetes Patients. asiglucagon is an analog of human glucagon that is stable in aqueous formulation, for the treatment of type 1 diabetes in a dual-hormone artificial pancreas pump containing both insulin and glucagon. Dasiglucagon, a stable peptide analog of human glucagon, is a fast and effective treatment option for severe hypoglycemia. Dasiglucagon was approved in March 2021.
| Catalog Number | I025550 |
| CAS Number | 1544300-84-6 |
| Synonyms | Dasiglucagon; ZP4207; ZP 4207; ZP-4207 |
| Molecular Formula | C152H222N38O50 |
| Purity | 98% |
| Solubility | To be determined |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | L-Threonine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-2-methylalanyl-L-alanyl-L-arginyl-L-alanyl-L-alpha-glutamyl-L-alpha |
| InChI | InChI=1S/C152H222N38O50/c1-73(2)55-99(133(222)171-98(47-51-116(206)207)132(221)183-111(71-194)144(233)189-122(80(11)197)149(238)239)174-137(226)105(61-85-65-161-91-32-21-20-31-89(85)91)178-129(218)93(34-23-25-53-154)172-146(235)119(75(5)6)187-139(228)103(57-81-27-16-14-17-28-81)176-131(220)97(46-50-115(204)205)170-130(219)96(45-49-114(202)203)167-123(212)76(7)164-127(216)94(35-26-54-160-151(157)158)166-124(213)77(8)165-150(240)152(12,13)190-145(234)107(64-118(210)211)180-134(223)100(56-74(3)4)173-135(224)101(59-83-36-40-87(198)41-37-83)175-128(217)92(33-22-24-52-153)168-142(231)109(69-192)184-136(225)102(60-84-38-42-88(199)43-39-84)177-138(227)106(63-117(208)209)179-143(232)110(70-193)185-148(237)121(79(10)196)188-140(229)104(58-82-29-18-15-19-30-82)181-147(236)120(78(9)195)186-113(201)67-162-126(215)95(44-48-112(156)200)169-141(230)108(68-191)182-125(214)90(155)62-86-66-159-72-163-86/h14-21,27-32,36-43,65-66,72-80,90,92-111,119-122,161,191-199H,22-26,33-35,44-64,67-71,153-155H2,1-13H3,(H2,156,200)(H,159,163)(H,162,215)(H,164,216)(H,165,240)(H,166,213)(H,167,212)(H,168,231)(H,169,230)(H,170,219)(H,171,222)(H,172,235)(H,173,224)(H,174,226)(H,175,217)(H,176,220)(H,177,227)(H,178,218)(H,179,232)(H,180,223)(H,181,236)(H,182,214)(H,183,221)(H,184,225)(H,185,237)(H,186,201)(H,187,228)(H,188,229)(H,189,233)(H,190,234)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H,238,239)(H4,157,158,160)/t76-,77-,78+,79+,80+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,119-,120-,121-,122-/m0/s1 |
| InChIKey | RZRMFQMNPDPAIX-AJTOSFMRSA-N |
| SMILES | CC(C[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)[C@H](O)C)=O)CO)=O)CCC(O)=O)=O)NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(C(C)(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@H]([C@H](O)C)NC(CNC([C@@H](NC([C@@H](NC([C@H](Cc1nc[nH]c1)N)=O)CO)=O)CCC(N)=O)=O)=O)=O)Cc2ccccc2)=O)=O)CO)=O)CC(O)=O)=O)Cc3ccc(O)cc3)=O)CO)=O)CCCCN)=O)Cc4ccc(O)cc4)=O)CC(C)C)=O)CC(O)=O)=O)C)=O)C)=O)CCCNC(N)=N)=O)C)=O)CCC(O)=O)=O)CCC(O)=O)=O)Cc5ccccc5)=O)=O)CCCCN)=O)Cc(c[nH]6)c7c6cccc7)=O)C |
| Reference | 1: Li S, Hu Y, Tan X, Wang D, Hu J, Zou P, Wang L. Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes. Expert Opin Pharmacother. 2020 Aug;21(11):1311-1318. doi: 10.1080/14656566.2020.1747432. Epub 2020 Apr 8. PMID: 32267182. |
